For millions of people using GLP-1 medications to treat obesity, the most daunting question isn’t how to lose the weight, but how to keep it off. The “maintenance phase” has long been the Achilles’ heel of metabolic medicine, often characterized by a grueling choice between lifelong high-dose injections or the inevitable rebound of weight regain.
New data from Eli Lilly suggests a more flexible path forward. In the ATTAIN-MAINTAIN trial, participants who had already achieved significant weight loss on an injectable GLP-1 and then switched to Foundayo—a once-daily oral medication—maintained their progress with remarkable stability. Over 52 weeks, those who switched to the oral formulation regained only 0.9 kg (approximately 2 lbs) of previously lost weight.
As a physician, I view this figure as more than just a statistical success; We see a potential shift in the clinical paradigm. The result suggests that Foundayo maintains weight loss in Lilly trials by approximating the continuity of an injectable after the “hard metabolic work” of initial weight induction has already been completed.
This finding arrives alongside results from the SURMOUNT-MAINTAIN trial, which examined the effects of reducing the dose of Zepbound, an injectable tirzepatide. Together, these studies address a critical gap in obesity care: providing patients with lower-burden maintenance options that prevent the rapid weight regain typically seen when these medications are discontinued entirely.
Bridging the Gap Between Injectables and Pills
The architecture of the ATTAIN-MAINTAIN trial was specifically designed to test a sequential switch. Rather than testing whether the oral pill could induce weight loss as effectively as a needle from day one, researchers asked what happens after a patient has plateaued on a maximum tolerated dose of an injectable, such as Wegovy, and then transitions to an oral daily dose.
The results indicate that the oral formulation can effectively “hold the line.” The 0.9 kg regain is negligible in a clinical context, suggesting that for many, the daily pill may be a viable alternative to weekly injections once the primary weight-loss goals are met. This represents particularly relevant for patients who develop “needle fatigue” or those who seek a more discreet, convenient administration method for long-term chronic care.
The necessity of active maintenance was underscored by the placebo groups in both the ATTAIN and SURMOUNT trials. Participants who stopped active therapy and moved to a placebo experienced rapid weight regain, reinforcing the medical consensus that obesity is a chronic condition requiring ongoing pharmacological or lifestyle intervention to prevent metabolic relapse.
The Trade-offs of Dose Reduction
While the switch to an oral pill showed high stability, the SURMOUNT-MAINTAIN trial looked at a different strategy: staying on an injectable but lowering the dose. In this arm, participants switched to a 5 mg dose of Zepbound.
The data revealed a “dose-reduction penalty.” Those on the lower 5 mg dose maintained all but 5.6 kg (about 12.3 lbs) of their prior loss, compared to zero loss in the group that remained on the maximum tolerated dose. While a 5.6 kg regain is more pronounced than the 0.9 kg seen with Foundayo, it must be viewed in proportion. With patients having previously lost between 22 kg and 24 kg, the trade-off for a lower dose may be acceptable for those who struggle with the side effects of higher-dose regimens.
| Trial | Maintenance Strategy | Weight Regain (Approx.) | Primary Focus |
|---|---|---|---|
| ATTAIN-MAINTAIN | Switch to Oral Foundayo | 0.9 kg | Delivery Method Switch |
| SURMOUNT-MAINTAIN | Zepbound 5 mg (Low Dose) | 5.6 kg | Dose Optimization |
| Both Trials | Placebo (Discontinuation) | Rapid Regain | Baseline Comparison |
Tolerability and the “Maintenance Context”
One of the primary hurdles for GLP-1 therapies is gastrointestinal distress. In the ATTAIN-MAINTAIN trial, the nausea rate for Foundayo was 18.8%. While not insignificant, the discontinuation rates tell a more nuanced story. Only 7.2% of participants in the Foundayo arm discontinued the drug due to adverse events, compared to 6.3% in the placebo arm—a near-wash that suggests the drug is well-tolerated when introduced as a maintenance tool rather than a first-exposure induction therapy.
The safety profile for the Zepbound 5 mg group was even cleaner, with zero discontinuations due to adverse events during the maintenance period. This suggests that reducing the dose not only helps maintain the bulk of weight loss but may significantly improve the long-term sustainability of the treatment by eliminating severe side effects.
The Regulatory Path and Insurance Hurdles
The clinical success of these trials now moves into the regulatory and financial arena. The primary focus for Eli Lilly will be whether the U.S. Food and Drug Administration (FDA) accepts the ATTAIN-MAINTAIN data as sufficient evidence to grant Foundayo a formal “maintenance indication” label.
This label is critical because it dictates how insurance companies and pharmacy benefit managers (PBMs) will handle the drug. If the FDA specifies that Foundayo is for “post-injectable-induction use,” payers may construct “step-therapy” criteria. This would mean a patient must first prove they can lose weight on an injectable before their insurance will cover the switch to the oral pill.
Such a sequence would create a structured clinical pathway: an intensive induction phase followed by a lower-burden maintenance phase. While this provides a clear medical roadmap, it could also create hurdles for patients who wish to start with an oral medication from the outset.
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or treatment.
The next major checkpoint for this therapy will be the FDA’s review of the maintenance indication for Foundayo. A positive ruling would formalize the transition from “weight loss” to “weight maintenance” as a distinct phase of treatment, potentially changing the standard of care for millions.
Do you think a daily pill is a viable alternative to weekly injections for long-term health? Share your thoughts in the comments or share this story with others navigating their weight loss journey.
